A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions

Lori J. Wirth, Jeffrey F. Krane, Yi Li, Megan Othus, Amy Moran, David M. Dorfman, Charles M. Norris, Laura Goguen, Marshall R. Posner, Robert I. Haddad, Monica M. Bertagnolli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This study evaluated changes in prostaglandin E2 (PGE2) levels and related biomarkers in oral premalignant lesions (OPL) in response to celecoxib treatment. Twenty-two subjects were enrolled and treated with celecoxib. Pretreatment and 12-week biopsies were done. Subjects whose biopsy showed ≥30% decrease in PGE2 remained on celecoxib for a total of 12 months when repeat biopsy was done. Biopsies were examined to assess degree of dysplasia, DNA ploidy, and immunohistochemical expression of BCL2, pAKT-Ser473, Ki-67, and CD31 (microvessel density). In 18 paired biopsies available at baseline and 12 weeks, mean normalized PGE2 levels decreased by 38% (P = 0.002). After 12 months, PGE2 decreased by 31% (P = 0.340). Twelve biopsies (67%; P = 0.0129) showed improvement in degree of dysplasia after 12 weeks, and 8 of 11 biopsies (73%; P = 0.0703) continued to show an improvement in the degree of dysplasia after 12 months. Trends suggested down-modulation of cyclooxygenase-2 and Ki-67 in some tissues, increased pAKT-Ser473 expression, and an inverse relationship between PGE2 and BCL2 expression. This study documents the feasibility of measuring potential surrogate endpoint biomarkers of chemopreventive agent response in OPLs. Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE2, after 12 weeks.

Original languageEnglish (US)
Pages (from-to)339-348
Number of pages10
JournalCancer Prevention Research
Volume1
Issue number5
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Celecoxib
Dinoprostone
Biomarkers
Biopsy
Cyclooxygenase 2
Ploidies
Feasibility Studies
Microvessels

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wirth, L. J., Krane, J. F., Li, Y., Othus, M., Moran, A., Dorfman, D. M., ... Bertagnolli, M. M. (2008). A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prevention Research, 1(5), 339-348. https://doi.org/10.1158/1940-6207.CAPR-07-0003

A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. / Wirth, Lori J.; Krane, Jeffrey F.; Li, Yi; Othus, Megan; Moran, Amy; Dorfman, David M.; Norris, Charles M.; Goguen, Laura; Posner, Marshall R.; Haddad, Robert I.; Bertagnolli, Monica M.

In: Cancer Prevention Research, Vol. 1, No. 5, 01.10.2008, p. 339-348.

Research output: Contribution to journalArticle

Wirth, LJ, Krane, JF, Li, Y, Othus, M, Moran, A, Dorfman, DM, Norris, CM, Goguen, L, Posner, MR, Haddad, RI & Bertagnolli, MM 2008, 'A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions', Cancer Prevention Research, vol. 1, no. 5, pp. 339-348. https://doi.org/10.1158/1940-6207.CAPR-07-0003
Wirth, Lori J. ; Krane, Jeffrey F. ; Li, Yi ; Othus, Megan ; Moran, Amy ; Dorfman, David M. ; Norris, Charles M. ; Goguen, Laura ; Posner, Marshall R. ; Haddad, Robert I. ; Bertagnolli, Monica M. / A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. In: Cancer Prevention Research. 2008 ; Vol. 1, No. 5. pp. 339-348.
@article{c865010aace546d5b5a1c3e3622d59bd,
title = "A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions",
abstract = "This study evaluated changes in prostaglandin E2 (PGE2) levels and related biomarkers in oral premalignant lesions (OPL) in response to celecoxib treatment. Twenty-two subjects were enrolled and treated with celecoxib. Pretreatment and 12-week biopsies were done. Subjects whose biopsy showed ≥30{\%} decrease in PGE2 remained on celecoxib for a total of 12 months when repeat biopsy was done. Biopsies were examined to assess degree of dysplasia, DNA ploidy, and immunohistochemical expression of BCL2, pAKT-Ser473, Ki-67, and CD31 (microvessel density). In 18 paired biopsies available at baseline and 12 weeks, mean normalized PGE2 levels decreased by 38{\%} (P = 0.002). After 12 months, PGE2 decreased by 31{\%} (P = 0.340). Twelve biopsies (67{\%}; P = 0.0129) showed improvement in degree of dysplasia after 12 weeks, and 8 of 11 biopsies (73{\%}; P = 0.0703) continued to show an improvement in the degree of dysplasia after 12 months. Trends suggested down-modulation of cyclooxygenase-2 and Ki-67 in some tissues, increased pAKT-Ser473 expression, and an inverse relationship between PGE2 and BCL2 expression. This study documents the feasibility of measuring potential surrogate endpoint biomarkers of chemopreventive agent response in OPLs. Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE2, after 12 weeks.",
author = "Wirth, {Lori J.} and Krane, {Jeffrey F.} and Yi Li and Megan Othus and Amy Moran and Dorfman, {David M.} and Norris, {Charles M.} and Laura Goguen and Posner, {Marshall R.} and Haddad, {Robert I.} and Bertagnolli, {Monica M.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1158/1940-6207.CAPR-07-0003",
language = "English (US)",
volume = "1",
pages = "339--348",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions

AU - Wirth, Lori J.

AU - Krane, Jeffrey F.

AU - Li, Yi

AU - Othus, Megan

AU - Moran, Amy

AU - Dorfman, David M.

AU - Norris, Charles M.

AU - Goguen, Laura

AU - Posner, Marshall R.

AU - Haddad, Robert I.

AU - Bertagnolli, Monica M.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - This study evaluated changes in prostaglandin E2 (PGE2) levels and related biomarkers in oral premalignant lesions (OPL) in response to celecoxib treatment. Twenty-two subjects were enrolled and treated with celecoxib. Pretreatment and 12-week biopsies were done. Subjects whose biopsy showed ≥30% decrease in PGE2 remained on celecoxib for a total of 12 months when repeat biopsy was done. Biopsies were examined to assess degree of dysplasia, DNA ploidy, and immunohistochemical expression of BCL2, pAKT-Ser473, Ki-67, and CD31 (microvessel density). In 18 paired biopsies available at baseline and 12 weeks, mean normalized PGE2 levels decreased by 38% (P = 0.002). After 12 months, PGE2 decreased by 31% (P = 0.340). Twelve biopsies (67%; P = 0.0129) showed improvement in degree of dysplasia after 12 weeks, and 8 of 11 biopsies (73%; P = 0.0703) continued to show an improvement in the degree of dysplasia after 12 months. Trends suggested down-modulation of cyclooxygenase-2 and Ki-67 in some tissues, increased pAKT-Ser473 expression, and an inverse relationship between PGE2 and BCL2 expression. This study documents the feasibility of measuring potential surrogate endpoint biomarkers of chemopreventive agent response in OPLs. Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE2, after 12 weeks.

AB - This study evaluated changes in prostaglandin E2 (PGE2) levels and related biomarkers in oral premalignant lesions (OPL) in response to celecoxib treatment. Twenty-two subjects were enrolled and treated with celecoxib. Pretreatment and 12-week biopsies were done. Subjects whose biopsy showed ≥30% decrease in PGE2 remained on celecoxib for a total of 12 months when repeat biopsy was done. Biopsies were examined to assess degree of dysplasia, DNA ploidy, and immunohistochemical expression of BCL2, pAKT-Ser473, Ki-67, and CD31 (microvessel density). In 18 paired biopsies available at baseline and 12 weeks, mean normalized PGE2 levels decreased by 38% (P = 0.002). After 12 months, PGE2 decreased by 31% (P = 0.340). Twelve biopsies (67%; P = 0.0129) showed improvement in degree of dysplasia after 12 weeks, and 8 of 11 biopsies (73%; P = 0.0703) continued to show an improvement in the degree of dysplasia after 12 months. Trends suggested down-modulation of cyclooxygenase-2 and Ki-67 in some tissues, increased pAKT-Ser473 expression, and an inverse relationship between PGE2 and BCL2 expression. This study documents the feasibility of measuring potential surrogate endpoint biomarkers of chemopreventive agent response in OPLs. Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE2, after 12 weeks.

UR - http://www.scopus.com/inward/record.url?scp=61549101866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549101866&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-07-0003

DO - 10.1158/1940-6207.CAPR-07-0003

M3 - Article

C2 - 19138978

AN - SCOPUS:61549101866

VL - 1

SP - 339

EP - 348

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 5

ER -